Sinovac cuts Covid-19 death risk by 84%, AZ and Pfizer by over 90%: Malaysia survey on 1.26m people

‘The Sinovac vaccine can reduce the risk of death among Covid-19 patients by up to 84%, the health ministry said today. Citing data from the real-world evaluation of Covid-19 vaccines under the Malaysia national Covid-19 immunisation programme (RECoVaM), the ministry said the Pfizer jab decreased the risk of death by 93%.

‘In a Twitter post, it said the AstraZeneca vaccine showed the best result, with the lowest rate of “breakthrough deaths”, with the study finding that the jab reduced the risk of deaths among Covid-19 patients by 96%. This was based on a survey led by the health ministry’s Institute for Clinical Research (ICR) on 1,261,270 individuals.’

Read here (Free Malaysia Today, Sept 24, 2021)

Covid-19 deaths among vaccinated rare, mostly Sinovac recipients

‘These deaths of the fully vaccinated, that occurred between June 7 and Sept 6, were mainly senior citizens (744; 80.6 percent), had comorbidities (750; 81.3 percent) - usually both (605; 65.6 percent). Deaths among those below 60 with no comorbidities only accounted for 33 cases (3.6 percent).

‘Based on Malaysiakini's analysis of the data, Sinovac vaccine recipients account for 710 out of 922 of these deaths (77.0 percent), even though Sinovac vaccine recipients only make up 51.5 percent of fully vaccinated people as of Sept 6 including the 14-day period after the second dose. In comparison, Pfizer vaccine recipients account for 206 deaths (22.3 percent) while accounting for 43.6 percent of the fully vaccinated population in Malaysia. 

‘In other words, there are 10.11 vaccine breakthrough deaths for every 100,000 people fully vaccinated with the Sinovac vaccine, and 3.47 per 100,000 for Pfizer recipients.’

Read here (Malaysiakini via YahooNews, Sept 10, 2021) 

Covid-19: What is coming our way? — Dr Amar-Singh HSS

‘We have all been occupied by the political situation in the country, but the Covid-19 virus is not. It is continuing its relentless march forward, whether we are focused on it or not. While an efficient government that deals with the pandemic decisively is crucial for the country, Malaysians need to be prepared for what is coming our way. I would like to share with you some possible scenarios for the coming weeks and months, and some thoughts and opinions based on current data.

• Continued recovery in the Greater Klang Valley
• Worsening crisis outside the Klang Valley
• Infections in children the next wave?
• Resolving Sinovac vaccine efficacy issues
• The myth of herd immunity and a resurgence of Delta as immunity wanes?

Read here (Code Blue, August 19, 2021)

Indonesia study finds China's Sinovac COVID-19 vaccine effective in medical staff

‘China's Sinovac Biotech COVID-19 vaccine was 98 per cent effective at preventing death and 96 per cent effective at preventing hospitalisation among a group of inoculated Indonesian medical staff, a study conducted by the country's health ministry has found.

‘The findings were based on data from 120,000 healthcare workers in Jakarta who had received the vaccine between January and March this year, lead researcher and health official Pandji Dhewantara told a briefing on Wednesday.’

Read here (Channel News Asia, May 12, 2021)

How a small city in Brazil may reveal how fast vaccines can curb Covid-19

‘The city of Serrana in Brazil is a living experiment. The picturesque place, surrounded by sugarcane fields, is nestled in the southeast of one of the countries hit hardest by COVID-19. By the end of March, daily deaths in Brazil surged to 3,000 on average a day, a high in a pandemic that has claimed more than 405,000 lives there — the second worst death toll of any country in the world behind only the United States. And as vaccines slowly trickle into the country, only about 15 percent of the population has gotten at least one shot.

‘Except in Serrana. There, nearly all the adults have gotten their shots. What happens next in this city could provide a glimpse of what the future of the pandemic could be — not only in Brazil but across the globe as vaccinations pick up.’

Read here (Science News, May 5, 2021)

China’s Sinovac Covid-19 vaccine 67% effective in preventing symptomatic infection: Chile govt report

‘China's Sinovac COVID-19 vaccine was 67% effective in preventing symptomatic infection, data from a huge real-world study inChile has shown, a potential boost for the jab which has come under scrutiny over its level of protection against the virus.

‘The CoronaVac vaccine was 85% effective in preventing hospitalizations and 80% effective in preventing deaths, the Chilean government said in a report, adding that the data should prove a "game changer" from the vaccine more widely.’

Read here (Reuters, Apr 17, 2021)

Are China’s Covid shots less effective? Experts size up Sinovac

‘The good news is the vaccines work extremely well in combating severe Covid infections, according to Fiona Russell from the Murdoch Children’s Research Institute in Melbourne and Paul Griffin, a professor from the University of Queensland in Brisbane. We asked them key questions about the merits of the Sinovac shot. Their comments have been edited and condensed for brevity.

‘How effective is the Sinovac vaccine really?

‘Russell: The Sinovac study was to look at how the vaccine works against the entire range of clinical symptoms, from mild infections to severe ones, including death. The efficacy data of about 50% is for very mild disease, requiring no treatment. For infections requiring some medical intervention, it’s about 84% and for moderate-to-severe Covid cases, it’s 100%.’

Read here (Bloomberg, Apr 14, 2021)

Indonesia satisfied with effectiveness of Chinese Covid-19 vaccine

‘Indonesia said on Monday (Apr 12) that it is satisfied with the effectiveness of the Sinovac coronavirus vaccine it is using, after the acknowledgement by China’s top disease control official that current vaccines offer low protection against the virus.

‘Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine programme, said the World Health Organization had found the Chinese vaccines had met requirements by being more than 50 per cent effective. She noted that clinical trials for the Sinovac vaccine in Indonesia showed it was 65 per cent effective.’

Read here (AP News, Apr 13, 2021)

Official: Chinese vaccines’ effectiveness low

‘In a rare admission of the weakness of Chinese coronavirus vaccines, the country’s top disease control official says their effectiveness is low and the government is considering mixing them to give them a boost. Chinese vaccines “don’t have very high protection rates,” said the director of the China Centers for Disease Control, Gao Fu, at a conference Saturday in the southwestern city of Chengdu.

‘Beijing has distributed hundreds of millions of doses in other countries while also trying to promote doubt about the effectiveness of Western vaccines. “It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunization process,” Gao said.’

Read here (AP News, Apr 11, 2021)

Sinovac Covid-19 vaccine appears safe, triggers antibodies in trial in children: Researcher

‘Sinovac Biotech's Covid-19 vaccine appears to be safe and able to trigger immune responses among children and adolescents, according to preliminary results from early and mid-stage trials, the company said late on Monday (March 22). The preliminary data was from Phase I and II clinical trials involving over 500 people between the ages of three and 17 who received two shots of either medium or low dosage of vaccine, or a placebo. Most adverse reactions were mild, Zeng Gang, a researcher with the company, told an academic conference in Beijing.’

Read here (Straits Times, Mar 23, 2021)

Khairy set to be first recipient of Sinovac Covid-19 vaccine this Thursday

‘Malaysia will start using the Sinovac Covid-19 vaccine this Thursday, with the Coordinating Minister for the National Covid-19 Immunisation Programme, Khairy Jamaluddin, becoming the first recipient of the Chinese-produced vaccine.

‘Announcing the matter in a press conference on the development of the National Covid-19 Immunisation Programme here today, Khairy said that he would receive the Sinovac vaccine at the Rembau Hospital, Negri Sembilan.’

Read here (Malay Mail, Mar 15, 2021)

Khairy welcomes private sector procuring approved Covid-19 vaccines

“With regards to the purchase of vaccines by the private sector, as I have mentioned yesterday, most of the vaccine manufacturers only carry out negotiations with governments,” Khairy responded to Najib in a comment on his Facebook post...

“But if there are private parties who are able to carry out negotiations with vaccine manufacturers, especially those that have received approval from the NPRA (National Pharmaceutical Regulatory Agency) (Pfizer, AstraZeneca, and Sinovac), please do so. I really welcome it,” added the science, technology and innovation minister. 

‘Previously, Malaysian-based pharmaceutical company Pharmaniaga Bhd announced that it planned to sell some of its Sinovac vaccine doses to the private sector. Pharmaniaga is undertaking the fill-and-finish processing of Sinovac’s vaccine. Solution Biologics, the distributor of Chinese CanSino’s vaccine, has also expressed plans to supply private health care providers with the vaccine, on top of selling 3.5 million doses to the Malaysian government.’ 

Read here (Code Blue, Mar 10, 2021)

From Pfizer to Moderna: Who's making billions from Covid-19 vaccines?

‘Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.

‘But other drugmakers, such as the British-Swedish AstraZeneca and the US pharma Johnson & Johnson, have pledged to provide their vaccines on a not-for-profit basis until the pandemic comes to an end.’

Also carried in this story are: Sinovac, Sputnik V, Novavax, CureVac 

Read here (The Guardian, Mar 6, 2021)

Malaysia approves Sinovac, AstraZeneca Covid-19 vaccines for use

‘Malaysia on Tuesday (Mar 2) granted conditional approval for the use of vaccines made by UK firm AstraZeneca and China's Sinovac, just days after launching its nationwide COVID-19 inoculation programme. Malaysia began its vaccination drive on Feb 24 using a shot developed by US drugmaker Pfizer and German partner BioNTech, as it tries to rein in a spike in infections and help revive an economy that recorded its worst slump in more than two decades last year.’

Read here (Channel News Asia, Mar 2, 2021)

China approves two more domestic Covid-19 vaccines for public use

‘China’s medical products regulator said on Thursday that it had approved two more COVID-19 vaccines for public use, raising the number of domestically produced vaccines that can be used in China to four. The two newly cleared vaccines are made by CanSino Biologics Inc (CanSinoBIO) and Wuhan Institute of Biological Products, an affiliate of China National Pharmaceutical Group (Sinopharm).

‘They join a vaccine from Sinovac Biotech approved earlier this month, and another from Sinopharm’s Beijing unit approved last year.

‘Prior to formal approval for wider public use by the National Medical Products Administration, millions of doses of the two Sinopharm vaccines and Sinovac shot had been administered in China’s vaccination program. The program targets select groups of people facing a higher risk of infection.’

Read here (Reuters, Feb 25, 2021)

It’s time to trust China’s and Russia’s vaccines

‘The fact is that no Covid-19 vaccine has been developed or released as transparently as it should have been. And while China and Russia may have botched their rollouts more than some Western companies, that doesn’t necessarily mean their vaccines are shoddy. The mounting evidence showing that the Chinese and Russian vaccines are reliable should be taken seriously, and fast, especially considering supply issues throughout the world...

‘What’s more, most big pharmaceutical companies in the West have resisted licensing their vaccines to non-Western manufacturers, and several wealthy countries are blocking a proposal by India and South Africa that the World Trade Organization temporarily suspend some intellectual property protections for Covid-19-related vaccines and treatments.

‘On the other hand, according to our latest analysis of data provided by the analytics firm Airfinity, Sinovac has already signed deals to export this year more than 350 million doses of its vaccine to 12 countries; Sinopharm, around 194 million doses to 11 countries; Sputnik V, about 400 million doses to 17 countries. All three manufacturers have stated publicly that they will have the capacity to produce up to 1 billion doses each in 2021. And all three have licensed their vaccines to local manufacturers in several countries.’

Read here (New York Times, Feb 5, 2021)

Sinovac applies for conditional approval of Covid-19 vaccine in China

‘China's medicine regulator is reviewing a second domestically developed COVID-19 vaccine for conditional approval. The CoronaVac inoculation, developed by Sinovac Biotech, has been given to tens of thousands of people in China under an emergency use program launched in July targeting specific groups with high infection risks. Regulators are also reviewing for approval a similar vaccine created by state-owned China National Pharmaceutical Group, known as Sinopharm...

‘China's COVID-19 vaccines have won approval in a dozen countries for emergency use, but the failure to publish detailed trial data could undermine public trust, a leading Chinese researcher said in a recent interview.

‘Ding Sheng, dean of Tsinghua University's School of Pharmaceutical Sciences and director of the Global Health Drug Discovery Institute (GHDDI), called for the original clinical trial data from Chinese experimental vaccines to be made public so that experts can better assess their efficacy and eliminate lingering safety concerns in China and abroad.’

Read here (Nikkei, Feb 4, 2021)

How Singapore picked its Covid-19 vaccines

‘Last June, Singapore sealed its first deal to buy Covid-19 vaccines - before any of the more than 200 vaccine candidates had even started their phase three clinical trials. It decided not to wait for the trials, and even paid a premium on the price, in order to secure some early stock of vaccines for people here at high risk, such as healthcare workers and the elderly. That was for the Moderna mRNA vaccine, which has yet to be approved for use here.

‘Singapore signed two more purchase agreements in August - with Sinovac which produces a traditional vaccine, and Pfizer-BioNTech which also uses mRNA. These purchases should provide sufficient vaccines for the entire adult population. But Singapore is buying more. Dr Benjamin Seet, who chaired the panel that picked the vaccines for Singapore, said several late-stage discussions are still ongoing with a handful of other companies - as part of a contingency plan should there be disruptions in the supply of purchased vaccines, delays in the delivery, or even the need for further booster shots.’

Read here (Straits Times, Feb 1, 2021) 

What about the Chinese Covid-19 vaccines? — Dr Musa Mohd Nordin

‘The Chinese vaccines are rapidly making inroads into the Malaysian vaccine market place. After the 39 per cent Pfizer-BioNTech, 10 per cent AstraZeneca-Oxford and 10 per cent COVAX vaccine advance bookings, there is now reported, a 22 per cent booking of the Sinovac vaccine. 

‘China’s Sinovac Lifesciences Co Ltd, manufactures the inactivated vaccine, CoronaVac which is administered intramuscularly, two doses, two weeks apart. And can be stored in a standard refrigerator at 2-8 degree Celsius, unlike the arctic temperatures required for the mRNA vaccines...’

Read here (Malay Mail, Jan 29, 2021) 

Just like Pfizer, China says vaccines can beat new strains

‘Virologists and vaccine specialists with China’s National Health Commission (NHC) said on Wednesday they had a detailed plan to upgrade homegrown vaccines against Covid-19 to “version 2.0” within two months to stop the spread of new mutant strains found across the United Kingdom and South Africa.

‘The claim coincided with Pfizer’s announcement on Wednesday that its Covid-19 vaccine works against mutated variants found in the UK and South Africa, according to a lab study. China’s claim comes as local firms SinoPharm and Sinovac crank out their Covid-19 shots for mass inoculations.’

Read here (Asia Times, Jan 28, 2021)